It began as a supply problem and evolved into a legal, regulatory, and political battle that touched hundreds of thousands of patients, a multibillion-dollar compounding pharmacy industry, two pharmaceutical giants, and the FDA itself. The story of GLP-1 drug shortages is still unfolding — and understanding it helps explain why access to these medications remains
It’s one of the most common questions patients ask before starting Wegovy, Zepbound, or Ozempic: What happens if I stop? The answer, while not what most people hope to hear, is important to understand before beginning treatment — because it changes how you and your doctor should think about these medications from the very start.
When Ozempic and Wegovy first captured public attention, the conversation centered almost entirely on one metric: pounds lost. And the weight loss results were dramatic enough to dominate headlines for years. But researchers, clinicians, and patients have been quietly uncovering something even more significant — these medications appear to be doing far more than shrinking
The headlines are everywhere: a new class of weight loss medications is producing results that doctors haven’t seen in decades. But buried beneath the excitement is a question that millions of Americans are confronting every month — can I actually afford this? The short answer is: it depends. The longer answer involves manufacturer coupons, insurance
If you’ve been following the buzz around weight loss medications, you may have noticed two names that keep appearing side by side: Mounjaro and Zepbound. They sound different, they’re marketed differently, and they even have different price tags — yet they contain the exact same active ingredient. So what’s really going on? Here’s the full
